search
Back to results

Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal (NUCOD)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Nurse-led Continuum of Care
Sponsored by
Kathmandu University School of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Diabetes Mellitus, Type 2 focused on measuring Continuum of care, Diabetes, Pre-diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • with confirmed pre-existing type II diabetes and prediabetes at the time of our screening (i.e., pre-existing diabetes or prediabetes)
  • with confirmed diagnosis of type II diabetes or prediabetes after our community screening process (i.e., newly diagnosed diabetes and prediabetes)
  • is not planning to relocate outside of the current place of living in next 2 years
  • is older than 18 years of age

Exclusion Criteria:

  • are not psychologically capable of communication
  • are diagnosed as type 1 diabetes

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Continuum of care

    Usual care

    Arm Description

    Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.

    The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.

    Outcomes

    Primary Outcome Measures

    Change in Glycated Hemoglobin (HbA1c) level
    The HbA1c will be measured using Boronate affinity chromatography (Axis-Shield, Norway)
    Change in the incidence of diabetes among individuals with pre-diabetes
    Electronic Health Record will be used to measure the incidence of diabetes

    Secondary Outcome Measures

    Change in Blood Pressure
    The blood pressure will be measured using mean of three measurements of systolic and diastolic blood pressure, using a Microlife automatic blood pressure measuring device
    Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol)
    LDL and HDL will be measured using the elimination method (Dialab, Austria); triglyceride using GPO-PAP (Dialab, Austria); and total cholesterol using CHOD-PAP (Dialab, Austria)
    Change in Body Mass Index
    Body Mass Index will be calculated as weight in kilograms divided by height in meters squared
    Change in the "Reach" of people participating in the program
    Reach will be measured by the number of people participating in the program divided by the number of people eligible to be recruited into the program
    Change in the "Adoption at the patient level" measured by the Summary of Diabetes Self-Care Activities Scale
    Adoption at the patient level will be measured by the proportion of people adherent to the clinical advice in lifestyle and self-care. These will be measured by the self-reported Summary of Diabetes Self-Care Activities scale. Five areas are assessed by the scale: Diet, Exercise, Blood-glucose testing, Foot care, and Smoking status. Scale of 0-7 is used. Higher the score better is the outcome.
    Change in the "Adoption at the patient level" measured by the Diabetes Treatment Satisfaction Questionnaire
    The Diabetes Treatment Satisfaction Questionnaire will be used to measure patient perception of the treatment. It is composed of eight questions, each of which is scored by patients on a scale ranging from zero (e.g., "very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). More satisfied the patient, better is the outcome.
    Change in the "Adoption at the clinic level"
    Adoption at the clinic level will be measured by a number of participants served using health records and examining nurses' adoption of intervention program through interviews

    Full Information

    First Posted
    October 15, 2019
    Last Updated
    October 16, 2019
    Sponsor
    Kathmandu University School of Medical Sciences
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04131257
    Brief Title
    Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal
    Acronym
    NUCOD
    Official Title
    Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal (NUCOD): Study Protocol for a Cluster Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 2019 (Anticipated)
    Primary Completion Date
    December 2020 (Anticipated)
    Study Completion Date
    December 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Kathmandu University School of Medical Sciences

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The study aims to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal.
    Detailed Description
    The purpose of this study will be to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal. We will conduct a two-arm, open-masked stratified cluster randomized controlled trial of a NUrse-led COntinuum of care for people with diabetes and pre-diabetes (NUCOD), with primary care centers (Outreach centers and Government health posts) as a unit of randomization. NUCOD will be delivered through the trained diabetes nurses in the community to the intervention group and the outcomes will be compared to the enhanced usual-treatment group at 6 and 12 months of the intervention. The primary outcome will be change in glycated hemoglobin (HbA1c) level among diabetes and progression to type 2 diabetes among pre-diabetes, and implementation outcomes measured using the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework. Outcomes will be analyzed on an intention to treat basis. The results of this trial will provide information about the effectiveness of the NUCOD program in improving clinical outcomes for diabetes and pre-diabetes individuals, and implementation outcomes for the organization.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Type 2
    Keywords
    Continuum of care, Diabetes, Pre-diabetes

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Care ProviderOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    1236 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Continuum of care
    Arm Type
    Experimental
    Arm Description
    Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.
    Arm Title
    Usual care
    Arm Type
    Active Comparator
    Arm Description
    The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Nurse-led Continuum of Care
    Intervention Description
    This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
    Primary Outcome Measure Information:
    Title
    Change in Glycated Hemoglobin (HbA1c) level
    Description
    The HbA1c will be measured using Boronate affinity chromatography (Axis-Shield, Norway)
    Time Frame
    Baseline, 6 months, 12 months
    Title
    Change in the incidence of diabetes among individuals with pre-diabetes
    Description
    Electronic Health Record will be used to measure the incidence of diabetes
    Time Frame
    6 months, 12 months
    Secondary Outcome Measure Information:
    Title
    Change in Blood Pressure
    Description
    The blood pressure will be measured using mean of three measurements of systolic and diastolic blood pressure, using a Microlife automatic blood pressure measuring device
    Time Frame
    Baseline, 6 months, 12 months
    Title
    Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol)
    Description
    LDL and HDL will be measured using the elimination method (Dialab, Austria); triglyceride using GPO-PAP (Dialab, Austria); and total cholesterol using CHOD-PAP (Dialab, Austria)
    Time Frame
    Baseline, 6 months, 12 months
    Title
    Change in Body Mass Index
    Description
    Body Mass Index will be calculated as weight in kilograms divided by height in meters squared
    Time Frame
    Baseline, 6 months, 12 months
    Title
    Change in the "Reach" of people participating in the program
    Description
    Reach will be measured by the number of people participating in the program divided by the number of people eligible to be recruited into the program
    Time Frame
    6 months, 12 months
    Title
    Change in the "Adoption at the patient level" measured by the Summary of Diabetes Self-Care Activities Scale
    Description
    Adoption at the patient level will be measured by the proportion of people adherent to the clinical advice in lifestyle and self-care. These will be measured by the self-reported Summary of Diabetes Self-Care Activities scale. Five areas are assessed by the scale: Diet, Exercise, Blood-glucose testing, Foot care, and Smoking status. Scale of 0-7 is used. Higher the score better is the outcome.
    Time Frame
    Baseline, 6 months, 12 months
    Title
    Change in the "Adoption at the patient level" measured by the Diabetes Treatment Satisfaction Questionnaire
    Description
    The Diabetes Treatment Satisfaction Questionnaire will be used to measure patient perception of the treatment. It is composed of eight questions, each of which is scored by patients on a scale ranging from zero (e.g., "very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). More satisfied the patient, better is the outcome.
    Time Frame
    Baseline, 6 months, 12 months
    Title
    Change in the "Adoption at the clinic level"
    Description
    Adoption at the clinic level will be measured by a number of participants served using health records and examining nurses' adoption of intervention program through interviews
    Time Frame
    6 months, 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: with confirmed pre-existing type II diabetes and prediabetes at the time of our screening (i.e., pre-existing diabetes or prediabetes) with confirmed diagnosis of type II diabetes or prediabetes after our community screening process (i.e., newly diagnosed diabetes and prediabetes) is not planning to relocate outside of the current place of living in next 2 years is older than 18 years of age Exclusion Criteria: are not psychologically capable of communication are diagnosed as type 1 diabetes
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Biraj M Karmacharya
    Phone
    +977 9802000029
    Email
    birajmk@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Rubee Dev
    Phone
    +86 15521049506
    Email
    meetrubss@hotmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Biraj M Karmacharya, PhD
    Organizational Affiliation
    Kathmandu University School of Medical Sciences
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    De-identified individual participant data for all primary and secondary outcome will be made available.
    IPD Sharing Time Frame
    Data will be available within 6 months of study completion.
    IPD Sharing Access Criteria
    Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.
    Citations:
    PubMed Identifier
    32471476
    Citation
    Xu DR, Dev R, Shrestha A, Zhang L, Shrestha A, Shakya P, Hughes JP, Shakya PR, Li J, Liao J, Karmacharya BM. NUrse-led COntinuum of care for people with Diabetes and prediabetes (NUCOD) in Nepal: study protocol for a cluster randomized controlled trial. Trials. 2020 May 29;21(1):442. doi: 10.1186/s13063-020-04372-5.
    Results Reference
    derived

    Learn more about this trial

    Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal

    We'll reach out to this number within 24 hrs